Business Description
Unicycive Therapeutics Inc
NAICS : 325110
SIC : 2834
ISIN : US90466Y1038
Share Class Description:
UNCY: Ordinary SharesDescription
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.96 | |||||
| Equity-to-Asset | -0.27 | |||||
| Debt-to-Equity | -0.21 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -12.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -73.4 | |||||
| 3-Year EPS without NRI Growth Rate | -48.2 | |||||
| 3-Year FCF Growth Rate | -63.7 | |||||
| 3-Year Book Growth Rate | 21.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.41 | |||||
| 9-Day RSI | 31.93 | |||||
| 14-Day RSI | 35.73 | |||||
| 6-1 Month Momentum % | 83.52 | |||||
| 12-1 Month Momentum % | -10.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.76 | |||||
| Quick Ratio | 0.76 | |||||
| Cash Ratio | 0.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -43.4 | |||||
| Shareholder Yield % | -1.65 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -3077.78 | |||||
| Net Margin % | -4525.04 | |||||
| FCF Margin % | -2708.59 | |||||
| ROE % | -925.24 | |||||
| ROA % | -176.48 | |||||
| ROIC % | -184.27 | |||||
| ROC (Joel Greenblatt) % | -3997.77 | |||||
| ROCE % | -807.05 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 25.42 | |||||
| EV-to-EBIT | -1.02 | |||||
| EV-to-EBITDA | -1.03 | |||||
| EV-to-Revenue | 46.04 | |||||
| EV-to-Forward-Revenue | 35.11 | |||||
| EV-to-FCF | -1.7 | |||||
| Earnings Yield (Greenblatt) % | -98.04 | |||||
| FCF Yield % | -49.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:UNCY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Unicycive Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.675 | ||
| EPS (TTM) ($) | -1.55 | ||
| Beta | 0 | ||
| Volatility % | 112.55 | ||
| 14-Day RSI | 35.73 | ||
| 14-Day ATR ($) | 0.118465 | ||
| 20-Day SMA ($) | 1.28 | ||
| 12-1 Month Momentum % | -10.37 | ||
| 52-Week Range ($) | 0.47 - 1.8227 | ||
| Shares Outstanding (Mil) | 34.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Unicycive Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Unicycive Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Unicycive Therapeutics Inc Frequently Asked Questions
What is Unicycive Therapeutics Inc(UNCY)'s stock price today?
The current price of UNCY is $1.07. The 52 week high of UNCY is $1.82 and 52 week low is $0.47.
When is next earnings date of Unicycive Therapeutics Inc(UNCY)?
The next earnings date of Unicycive Therapeutics Inc(UNCY) is 2024-05-16 Est..
Does Unicycive Therapeutics Inc(UNCY) pay dividends? If so, how much?
Unicycive Therapeutics Inc(UNCY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers